WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 2, 2020-- ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 38 th Annual J.P.
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 31, 2019-- ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 23, 2019 the compensation committee of the Company’s Board of Directors granted a
Top-Line Data from New Pivotal Single-Arm Trial, SORAYA, Expected in First Half of 2021 Confirmatory MIRASOL Trial for Mirvetuximab on Track to Start by Year-End Conference Call to be Held at 8:00 a.m. ET Today WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 17, 2019-- ImmunoGen Inc.
Data Demonstrating Potential in AML and BPDCN Presented During Oral Presentation; Dose and Schedule Selected for Further Development Preclinical Combination Data Also Presented; Support Further Evaluation of IMGN632 Doublets and Triplet in AML WALTHAM, Mass. --(BUSINESS WIRE)--Dec.
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 26, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Piper Jaffray Healthcare
Updated Phase 1 Data to be Highlighted in Oral Presentation Demonstrate Tolerable Safety Profile and Encouraging Activity in AML and BPDCN Preclinical Data for IMGN632 in Combination with Azacitidine and Venetoclax Support Clinical Evaluation of Doublets and Triplet in AML WALTHAM, Mass.
Full Mirvetuximab Soravtansine Phase 3 FORWARD I and Initial Phase 1b FORWARD II Triplet Data Presented at ESMO Phase 3 MIRASOL Trial for Mirvetuximab in Ovarian Cancer on Track to Start by Year-End Updated IMGN632 AML and BPDCN Monotherapy Data Accepted as Oral Presentation at ASH Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 18, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
FORWARD II Triplet Combination Demonstrates Encouraging Anti-Tumor Activity Preliminary Findings Support Ongoing Study in Platinum-Sensitive Patients WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 29, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug
FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRα) High Patients Favorable Tolerability and Differentiated Safety Profile Observed with Mirvetuximab Monotherapy Compared to Chemotherapy Exploratory Analyses